Two join to work on skincare
Kao has signed an agreement with its Japanese compatriot Daiichi Sankyo Healthcare, a specialist in over-the-counter (OTC) drugs, to collaborate in joint development in skin care, using each other's skin- and health-related fundamental and formulation technologies. Daiichi Sankyo Healthcare will use Kao's skin product formulation technology to develop OTC drugs.
Kao, which has hitherto used its capabilities in surfactants and life sciences to create skin care and hair care products in its Health and Beauty Care Business, said that this in line with its ‘Precision Life Care’ approach, under which it has “accelerated R&D of various health-related technologies to produce individualised solutions meeting every person's needs”.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
